Skip to main navigation Skip to search Skip to main content

A longitudinal analysis of pneumococcal vaccine serotypes in pneumonia patients in Germany

  • Christina Bahrs
  • , Miriam Kesselmeier
  • , Martin Kolditz
  • , Santiago Ewig
  • , Gernot Rohde
  • , Grit Barten-Neiner
  • , Jan Rupp
  • , Martin Witzenrath
  • , Tobias Welte
  • , Mathias W. Pletz*
  • *Corresponding author for this work
  • Center for Infectious Diseases and Infection Control
  • Friedrich Schiller University Jena
  • University of Vienna
  • Institute of Medical Statistics
  • Universitätsklinikum Carl Gustav Carus
  • Thoraxzentrum Ruhrgebiet
  • EVK Herne and Augusta-Kranken-Anstalt Bochum
  • Medical Clinic I
  • Johann Wolfgang Goethe-University
  • German Center for Lung Research (DZL)
  • CAPNETZ STIFTUNG
  • Charite - Universitatsmedizin Berlin
  • University of Freiburg
  • Hannover Medical School

Abstract

In Germany, the recently approved 20-valent pneumococcal conjugate vaccine had a substantially higher coverage against pneumonia in adults than the 13-valent vaccine, while the coverage gap compared to the 23-valent polysaccharide vaccine was small https://bit.ly/3q4skov

Original languageEnglish
JournalEuropean Respiratory Journal
Volume59
Issue number2
ISSN0903-1936
DOIs
Publication statusPublished - 01.02.2022

Funding

(CM-COVID). This study was supported by an unrestricted grant from Pfizer. Teva, and research funding from Actelion, Bayer Health Care, Biotest, partly supported by a grant of the Federal Ministry of Education and Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Research Areas and Centers

  • Academic Focus: Center for Infection and Inflammation Research (ZIEL)

Fingerprint

Dive into the research topics of 'A longitudinal analysis of pneumococcal vaccine serotypes in pneumonia patients in Germany'. Together they form a unique fingerprint.

Cite this